Get App

Time to reset economy

SENSEX NIFTY
you are here:

Vivanza Biosciences Ltd.

BSE Live

Jan 09, 16:00
13.10 0.04 (0.31%)
Volume
AVERAGE VOLUME
5-Day
44
10-Day
34
30-Day
37
100
  • Prev. Close

    13.06

  • Open Price

    13.10

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

(%)
Volume
No Data Available
  • Prev. Close

  • Open Price

  • Bid Price (Qty.)

    ()

  • Offer Price (Qty.)

    ()

Vivanza Biosciences is not listed on NSE

ANNOUNCEMENTS ON Vivanza Bio

  • Jun 29, 2019 15:26 Source: BSE

    Vivanza Biosciences - Closure of Trading Window

    We hereby would like to inform that the trading window shall remain close from Monday, July 1,2019 till 48 hours after the declaration of financial results for the quarter ended June 30, 2019. The designated persons and their immediate relatives will not trade in securities when trading window is closed.

  • May 21, 2019 16:59 Source: BSE

    Vivanza Biosciences - Outcome of Board Meeting

    The Board of Directors of the Company in its meeting held on May 21, 2019 has considered and approved the Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Year ended March 31, 2019.

  • May 21, 2019 16:56 Source: BSE

    Vivanza Biosciences - Results- Financial Results For March 31, 2019.

    The Board of Directors of the Company in its meeting held on May 21, 2019 has considered and approved the Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Year ended March 31, 2019.

  • May 15, 2019 15:37 Source: BSE

    Vivanza Biosciences - Board Meeting Intimation for Consideration And Approval Of Standalone And Consolidated Audited Financial Results For The Quarter And Year Ended March 31, 2019.

    Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2019 ,inter alia, to consider and approve 1) Standalone and Consolidated Audited Financial Results for the Quarter and Year ended March 31, 2019 as per Regulation 33 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015. 2) Any other business with the permission of chair.

  • Apr 30, 2019 17:40 Source: BSE

    Vivanza Biosciences - Compliances-Certificate under Reg. 54 (5) of SEBI (DP) Regulations, 1996

    We hereby enclose the Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 received from Purva Sharegistry (India) Private Limited, Registrar and Share Transfer Agent (RTA) of the Company, for the period ended on 31/03/2019.

  • Apr 30, 2019 12:27 Source: BSE

    Vivanza Biosciences - Compliances- Certificate Under Regulation 40 (9) For The Half Year Ended On 31/03/2019.

    Compliance Certificate under Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended on 31/03/2019.

  • Apr 30, 2019 12:21 Source: BSE

    Vivanza Biosciences - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

    Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

    Sr. No. Particulars Details
    1Name of CompayVivanza Biosciences Ltd
    2CININE984E01027
    3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0
    4Highest Credit Rating during the previous FY NA
    4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
    5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE


    We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No



    Name of the Company Secretary: Bhaskar Bhattacharya
    Designation: Managing Director
    EmailId: info@vivanzabiosciences.com
    Name of the Chief Financial Officer: Jainil Bhatt
    Designation: Chief Financial Officer
    EmailId: info@vivanzabiosciences.com

    Date: 30/04/2019

    Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

  • Apr 24, 2019 15:56 Source: BSE

    Vivanza Biosciences - Compliances- Compliance Certificate For The Period Ended 31St March, 2019.

    Compliance Certificate under Regulation 7(3) of SEBI (Listing Obligations & Disclosure Requirements)Regulations, 2015 for half year ended on 31st March, 2019 i.e., for the period from 1st October, 2018 to 31st March, 2019.

  • Apr 20, 2019 14:46 Source: BSE

    Vivanza Biosciences - Shareholding for the Period Ended March 31, 2019

    Vivanza Biosciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here

  • Apr 20, 2019 13:35 Source: BSE

    Vivanza Biosciences - Statement Of Investor Complaints For The Quarter Ended March 2019

    No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
    0110
    Name of the Signatory :- Bhaskar Bhattacharya
    Designation :- Director

BOARD MEETING

Meeting Date : Jan 28, 2020
Remark : Quarterly Results